OP0270 SENSITIVITY OF THE ACR/EULAR CLASSIFICATION CRITERIA IN A MULTICENTER ITALIAN COHORT OF PATIENTS WITH OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS): IMPLICATIONS FOR CLINICAL PRACTICE

作者
Francesca Ruffilli,Francesca Crisafulli,C. Nalli,A.C. Pozzi,Guerrino Voltarel,Carlo Garaffoni,Marcello Govoni,Alessandra Bortoluzzi,A. Tincani
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84: 222-223 被引量:1
标识
DOI:10.1016/j.ard.2025.05.280
摘要

Background: ACR and EULAR recently developed new classification criteria for antiphospholipid syndrome (APS) [1]. Several studies have evaluated the impact of these criteria on existing APS cohorts, demonstrating greater specificity but lower sensitivity compared to the previous Sydney criteria. However, there has been limited focus on specifically assessing the sensitivity of these criteria in populations where obstetric complications are the predominant manifestation of the disease. Objectives: This study aims to assess the sensitivity of the ACR/EULAR classification criteria in a cohort of patients with primary obstetric APS (OAPS), as diagnosed by experienced rheumatologists. As a secondary objective, we assessed the occurrence of new events during follow-up. Methods: A retrospective observational study was conducted on patients with OAPS, followed at two Italian centers between January 2006 and December 2023. Patients with secondary APS were excluded. Patients' records, including demographic data, clinical history, laboratory results, and clinical disease characteristics, were collected using a web-based database, along with information on the fulfillment of the Sydney and ACR/EULAR classification criteria. When available, data at 12 months after diagnosis were analyzed. The results were analyzed descriptively and reported as numbers and percentages (%) for categorical variables, and as mean values (SD) for continuous variables. Results: We enrolled 121 women diagnosed with OAPS (demographic and laboratory characteristics in Table 1). Twenty-six (22%) patients were classified as APS based on the ACR/EULAR criteria, compared to 91 (75%) who met the Sydney criteria. Patients who fulfilled the new classification criteria were younger (p=0.014) compared to those who did not meet these criteria, and they exhibited a significantly higher prevalence of triple aPL positivity (p = 0.001), indicative of a high-risk aPL profile. Early miscarriages were significantly underrepresented in the ACR/EULAR classification criteria group (23% vs 96%, p<0.001). In contrast, preterm births and severe placental disorders were more frequent in this group (75% vs 3%, p<0.001). Furthermore, venous thrombotic events and thrombocytopenia were significantly more frequent among the classifiable patients (p= 0.001). Serologically, these patients exhibited higher persistent LAC positivity (p = 0.010) and a greater frequency of high-titer IgG aPL positivity, and a lower frequency of moderate/high-titer IgM aPL positivity and medium-titer IgG aPL positivity (p = 0.002). The sensitivity of the ACR/EULAR criteria in our cohort was 20.4%, substantially lower compared to the Sydney criteria (77.8%). Among the 93 patients followed after diagnosis, 15% experienced at least one new obstetric event, with early miscarriages being the most common, followed by placental disorders and fetal deaths after 10 WG. No thrombotic events occurred during follow-up. One additional patient was classified as having APS according to the new criteria during this period. Patients with new obstetric events had higher rates of congenital thrombophilia (p = 0.004) and increased triple aPL positivity (p = 0.070) than those without new events. Notably, although no significant differences were found between patients classified and those not classified at baseline, a higher percentage of patients with new obstetric events met the Sydney criteria at baseline (79%), compared to a low percentage of patients classifiable according to the ACR/EULAR criteria (21%) (Figure 1). Conclusion: In our cohort, the ACR/EULAR classification criteria demonstrated low sensitivity, with over three-quarters of diagnosed OAPS patients not meeting the new criteria. This discrepancy is largely due to the limited weight assigned to recurrent fetal losses and isolated IgM antibody positivity. Patients who met the ACR/EULAR criteria appear to exhibit a more severe disease phenotype with an earlier onset. However, these criteria seem to exclude less severe but more common phenotypes observed in real-world populations, which still warrant physician attention. Additionally, the new criteria identify a smaller proportion of patients who develop new events during follow-up compared to the Sydney criteria. The new classification criteria have high specificity for selecting severe patients for research purposes. As previously stated, classification criteria should not be used as diagnostic criteria, particularly in the context of OAPS. REFERENCES: [1] Barbhaiya M et al. Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. Figure 1Fulfillment of the ACR/EULAR classification criteria and the Sydney classification criteria at baseline among patients who developed new obstetric events within 12 months of follow-up. Table 1Demographic and laboratory characteristics.TotalN 1 = 121ACR/EULARN 1 = 26No ACR/EULARN 1 = 95P-valueCaucasian ethnicity102 (84%)21 (80.8%)81 (85.3%)0.6Age at diagnosis (yrs)35 (± 6)33 (± 4)35 (± 7)0.014BMI (kg/m 2 )24.7 (± 5.1)25.4 (± 5.6)24.5 (± 4.9)0.5Current smokers11 (9.1%)3 (11.5%)8 (8.4%)0.7Inherited thrombophilia43 (36%)7 (26.9%)36 (37.9%)0.3Arterial hypertension16 (13.2%)7 (26.9%)9 (9.5%)0.043Autoimmune thyroiditis17 (14%)2 (7.7%)15 (15.8%)0.4LAC28 (23.1%)13 (50%)15 (15.8%)<0.001IgG aCL51 (42.1%)17 (65.4%)34 (35.8%)0.007IgM aCL30 (24.8%)1 (3.8%)29 (30.5%)0.005IgG aβ2GPI52 (43%)16 (62.5%)36 (37.9%)0.031IgM aβ2GPI37 (30.6%)9 (34.6%)28 (29.5%)0.6Triple aPL positivity24 (19.8%)11 (42.3%)13 (13.7%)0.001C3 (mg/dl)121 (± 28)122 (± 37)120 (± 25)0.9C4 (md/dl)24 (± 8)24 (± 9)24 (± 8)> 0.9 1: N (%), Mean (± SD ) Abbreviations : aB2GPI: anti-B2glycoprotein I; aCL: anticardiolipin; aPL: antiphospholipid; BMI: body mass index; LAC: lupus anticoagulant. Acknowledgements: NIL . Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
田様的应助被科研通管家采纳,获得10
刚刚
刚刚
一颗苹果的应助被科研通管家采纳,获得10
刚刚
刚刚
科研通AI6.2的应助被cc采纳,获得10
刚刚
传奇3的应助被科研通管家采纳,获得10
刚刚
刚刚
楚轩之圣的应助被科研通管家采纳,获得10
刚刚
Hello的应助被科研通管家采纳,获得10
刚刚
Maestro_S的应助被科研通管家采纳,获得10
刚刚
风吹麦浪的应助被科研通管家采纳,获得10
刚刚
Ava的应助被科研通管家采纳,获得10
1秒前
一颗苹果的应助被科研通管家采纳,获得10
1秒前
1秒前
初景的应助被科研通管家采纳,获得20
1秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
1秒前
上官若男的应助被科研通管家采纳,获得10
1秒前
1秒前
疯狂加载ing的应助被369ninja采纳,获得10
2秒前
乐乐的应助被剪头采纳,获得10
2秒前
每㐬山风完成签到,获得积分10
2秒前
小油菜发布了新的文献求助10
5秒前
5秒前
小卢发布了新的文献求助10
5秒前
豆角焖面关注了科研通微信公众号
5秒前
挚友发布了新的文献求助10
6秒前
7秒前
7秒前
彭于晏的应助被HH采纳,获得10
8秒前
8秒前
风吹麦浪的应助被汤圆采纳,获得10
9秒前
9秒前
10秒前
11秒前
璇璇发布了新的文献求助10
11秒前
komorebi发布了新的文献求助10
12秒前
和谐夏烟完成签到,获得积分10
12秒前
qin202569发布了新的文献求助10
12秒前
orixero的应助被小卢采纳,获得10
13秒前
无糖薄荷糖完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184508
求助须知:如何正确求助?哪些是违规求助? 9573479
关于积分的说明 21831986
捐赠科研通 7781752
什么是DOI,文献DOI怎么找? 3434372
关于科研通互助平台的介绍 2558482
邀请新用户注册赠送积分活动 2480962